Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

Niraparib approved for all-comers whose tumors responded to chemotherapy Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency. The FDA restricted ...

The use of PARP inhibitors for the treatment of patients with BRCA1/2 mutations represents a milestone in genomically-directed therapies. Olaparib and talazoparib have shown to significantly extend ...

SAN DIEGO -- Saruparib, an investigational selective PARP1 inhibitor, showed promising activity in patients with certain homologous recombination repair (HRR)-deficient breast cancers, while limiting ...

Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...

A new study confirmed an elevated risk for myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) after poly(ADP-ribose) polymerase (PARP) inhibitor therapy in women with ovarian cancer and ...

Please provide your email address to receive an email when new articles are posted on . Saruparib at 60 mg/day demonstrated deep, durable responses with a high response rate and tumor reduction in ...

About Artios Pharma Ltd. Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of ...

Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...